The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the list price for GLP-1 drugs can range between $936 and $1,349 before ...

Safety Concerns and Liability Issues for GLP-1 Drugs GLP-1 medications ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements ...

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. And buy Drew’s book, The ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider. Join the conversation, on Tuesday 28th January @ 10 ...